Skip to main content

Advertisement

Table 3 The estimates of TG STD (t), \(R_{\textit {PM}}^{2}\), \({R_{D}^{2}}\), \({\rho _{W}^{2}}\), and \(R_{\textit {BS}}^{2}(t)\), including 95 % bootstrap confidence intervals from 1000 replicates, in real data sets at 3 time points. The time points T1, T2, and T3 at which TG STD (t) and \(R_{\textit {BS}}^{2}(t)\) are evaluated in all data sets are the 25th, 50th, and 75th quantile of the follow-up period, i.e. the time to the last event, in each study. Therefore, T1, T2, and T3 are different in each study

From: The extension of total gain (TG) statistic in survival models: properties and applications

  Est. TG STD (t) at 3 time points     Est. \(R_{\textit {BS}}^{2}(t)\) at 3 time points
Study \(\widehat {{TG}}_{\textit {STD}}{(T}_{1}{)}\) \( \widehat {{TG}}_{\textit {STD}}{(T}_{2}{)}\) \(\widehat {{TG} }_{\textit {STD}}{(T}_{3}{)}\) \(\widehat {{R}}_{\textit {PM}}^{2}\) \( \widehat {{R}}_{D}^{2}\) \(\widehat {{\rho }}_{W}^{2}\) \( \widehat {{R}}_{\textit {BS}}^{2}{(T}_{1}{)}\) \(\widehat {{R }}_{\textit {BS}}^{2}{(T}_{2}{)}\) \(\widehat {{R}}_{\textit {BS}}^{2} {(T}_{3}{)}\)
Breast 0.32 0.33 0.35 0.27 0.28 0.36 0.12 0.16 0.20
cancer (0.27-0.37) (0.28-0.38) (0.30-0.40) (0.21-0.35) (0.21-0.35) (0.29-0.47) (0.07-0.18) (0.10-0.21) (0.14-0.25)
Lymphoma 0.28 0.31 0.36 0.23 0.23 0.32 0.16 0.22 0.24
  (0.16-0.40) (0.18-0.44) (0.21-0.50) (0.11-0.42) (0.11-0.40) (0.15-0.53) (0.02-0.24) (0.05-0.34) (0.07-0.38)
PBC 0.58 0.62 0.56 0.56 0.65 0.60 0.38 0.47 0.47
  (0.52-0.65) (0.54-0.70) (0.50-0.62) (0.48-0.65) (0.55-0.74) (0.53-0.68) (0.19-0.52) (0.38-0.58) (0.34-0.57)
Renal 0.34 0.37 0.41 0.27 0.26 0.33 0.24 0.27 0.19
cancer (0.28-0.40) (0.31-0.42) (0.36-0.46) (0.21-0.36) (0.20-0.33) (0.27-0.42) (0.16-0.31) (0.21-0.34) (0.11-0.26)
Prostate 0.22 0.24 0.26 0.13 0.13 0.18 0.06 0.11 0.10
cancer (0.17-0.27) (0.19-0.29) (0.21-0.32) (0.09-0.20) (0.09-0.21) (0.13-0.27) (0.02-0.10) (0.06-0.15) (0.05-0.14)